 |
| Professor Eva Segelov |
Professor Segelov comes from the University of New South
Wales where she was a clinical academic and a senior staff specialist in
medical oncology. She previously worked
at the Southwest Sydney Clinical School at Liverpool Hospital and St Vincent’s
Clinical School at St Vincent’s Hospital, Sydney.
While her clinical focus has been in the management of
patients with breast, upper and lower gastrointestinal cancer and
neuroendocrine tumours, Professor Segelov’s research interests are in clinical trials
and associated translational research.
She has led multiple national and international trials.
“I am extremely excited to be taking on this new position at
MHTP—the mission to lead the transformation of the Medical Oncology Department
into a world-class patient-centered academic cancer centre through the links
with Monash University was my motivation for moving cities,” said Professor
Segelov.
“The MHTP enables research excellence in clinical trials and
translational research as well as the opportunity to collaborate with
world-renowned colleagues in state-of-the-art facilities.”
“I hope to provide leadership and nurturing to the excellent
staff already at Monash Health and MHTP and to grow the clinical trials
portfolio and the productivity from the associated research,” said Professor
Segelov.
Professor Segelov plans to be a vocal advocate for
patient-focussed oncology services and research across the precinct.
As well as serving as a Board member of the Australasian
Gastrointestinal Trials Group (AGITG) and Convenor of the AGITG Annual
Scientific Meeting, Professor Segelov is the Gastrointestinal Chair for the
Clinical Oncology Society of Australia (COSA). She is also the co-Track Chair for GI Cancer
at the ESMO Asia annual conference and the Co-Founder of The Commonwealth
Neuroendocrine Tumour Collaboration (CommNETS), an international research
organisation between Australia, Canada and New Zealand.
